Sodium thiosulfate

Drug Profile

Sodium thiosulfate

Alternative Names: STS - Fennec

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Oregon Health & Science University
  • Developer Fennec Pharmaceuticals
  • Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Sensorineural hearing loss

Most Recent Events

  • 30 May 2017 Fennec Pharmaceuticals initiates a Named Patient Programme for Sensorineural hearing loss in Europe
  • 30 Mar 2017 Fennec plans to have regulatory agency scientific advice meetings with the US FDA and EMA on the timelines for the NDA and MAA submission for Sodium thiosulfate for the prevention of cisplatin-induced hearing loss in children with localised disease
  • 01 Dec 2016 Fennec Pharmaceuticals completes a phase III trial in Sensorineural hearing loss (Chemotherapy-induced, In children, Prevention) in USA and Canada (NCT00716976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top